Case Study: QED Therapeutics accelerates rare cancer drug launch with Clarify Health analytics

QED Therapeutics accelerates launch of rare cancer drug with analytics-driven insights into its niche market

QED Therapeutics, a precision medicine biotechnology company and an affiliate of BridgeBio Pharma, needed to rapidly build an evidence-based commercial strategy ahead of launch for infigratinib, its first-in-class treatment for rare cholangiocarcinoma (CCA). With a tiny patient population, narrow eligibility criteria, and time pressure from the approaching FDA fast-track launch, the team needed to identify the right patients, understand first-line treatment patterns, and assess genetic testing and physician prescribing behavior.

QED Therapeutics selected Clarify Health’s Clarify Growth analytics service to analyze longitudinal patient-level data and uncover insights on CCA patient journeys, provider characteristics, treatment history, and testing utilization. Clarify Health found about 26,000 CCA patients in the U.S. from 2016–2018, revealed that many eligible patients had not received first-line treatment or genetic testing, and showed that genetically tested patients were nearly twice as likely to receive first-line therapy A+E. These findings helped QED Therapeutics shift its launch strategy toward educating patients and physicians about testing and treatment.

QED Therapeutics

Carl Dambkowski

Chief Strategy Officer